![Cancer advances, inc.](/api/images/company-pic/0-1525985-company.jpg)
Contact us
About company
Cancer Advances is a biotechnology company focused on impacting human health and the progression of gastrointestinal cancers by enhancing the adaptive immune system. The company is led by an experienced management team and has a broad intellectual property portfolio. Cancer Advances is a wholly owned subsidiary of Cato BioVentures. The company's lead compound, Polyclonal Antibody Stimulator (PAS), is an immunomodulator used to treat gastrointestinal cancer. Please visit their Product page for more information on what is in development.
US
Unknown
Not verified company
Business transparency
- Did not verified company info
- Ask their customers for reviews
- Did not replied to negative reviews